Cancer preventive effect of pegylated interferon α‐2b plus ribavirin in a real‐life clinical setting in Japan: PERFECT interim analysis

Watanabe, Sumio; Enomoto, Nobuyuki; Koike, Kazuhiko; Izumi, Namiki; Takikawa, Hajime; Hashimoto, Etsuko; Kumada, Hiromitsu; Imawari, Michio

doi:10.1111/j.1872-034x.2011.00847.x

Cited by 19 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between response to PEG IFN/RBV and SNP associated with IL28B was concurrently reported by two other groups who also employed GWAS 8,9 . The IL28B polymorphism was highly predictive of the response to PEG IFN/RBV therapy in Japanese chronic hepatitis C (CHC) patients 10–12 . However, this was not always the case.…”

Section: Introductionmentioning

confidence: 84%

Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

Saito¹,

Ito²,

Sugiyama³

et al. 2012

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 84%

Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

Saito¹,

Ito²,

Sugiyama³

et al. 2012

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many studies have reported that antiviral therapy is useful as a radical treatment for hepatitis C, and hepatocarcinogenesis can be inhibited by achieving SVR [6,22,23,24]. However, therapies involving IFN are sometimes challenging due to adverse events.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Telaprevir-Based Antiviral Treatment for Elderly Patients with Hepatitis C Virus

Takita

Hagiwara²,

Kudo³

et al. 2014

Oncology

View full text Add to dashboard Cite

Background: Telaprevir-based antiviral therapy has been the primary treatment for chronic hepatitis C genotype 1 at a high viral load since November 2011. On the other hand, a number of patients have been reported to require withdrawal from or reduced doses of drugs due to side effects, such as eruptions, anemia, and renal dysfunction. In addition, as hepatitis C patients are growing older, it is imperative to investigate the tolerability of triple combination therapy for elderly patients. Subjects and Methods: The study subjects comprised 35 patients who received telaprevir combination therapy after November 2011. They were divided into group A (age: <65 years; n = 21) and group B (age: ≥65 years; n = 14) in order to compare the treatment completion rate, sustained virological response at week 24 (SVR24), and adverse events between the groups. Results: The treatment completion rate was 82.8% (29/35) in all subjects, 90.4% (19/21) in group A, and 78.5% (11/14) in group B. The rate was lower in group B but without a significant difference between the groups (p = 0.804). The SVR24 rate was 88.5% (31/35) in all subjects, 90.4% (19/21) in group A, and 85.7% (12/14) in group B, without a significant difference between the groups (p = 0.161). Conclusion: Although the incidence of anemia was higher in group B, there was no significant difference in the treatment completion or SVR24 rate between the groups. Telaprevir combination therapy is suggested to be tolerable for elderly hepatitis C patients.

show abstract

“…Collectively, these results suggest that the carcinogenic process in patients with chronic HCV infection is enhanced by high levels and fluctuations of alanine aminotransferase, and indicate a close relationship between suppression of inflammatory necrosis of hepatocytes and a lower incidence of hepatocellular carcinoma in patients with HCV-associated chronic liver disease. Recent studies based on interferon plus ribavirin combination therapy also showed that the attainment of sustained virological response or lower levels of alanine aminotransferase after ribavirin combination therapy could reduce the rates of hepatocellular carcinoma [15,16], but the small numbers of patients with compensated cirrhosis (5% or less of all patients) were recruited. The present study 1 based on the patients with compensated cirrhosis showed that rates of sustained virological response and sustained biochemical response in HCV-2a/2b were high rates of 70 and 78%, and that rates of sustained biochemical response (57%) were significantly higher than those of sustained virological response (34%) in HCV-1b.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

et al. 2012

Self Cite

View full text Add to dashboard Cite

Objective: Anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus (HCV)-related compensated cirrhosis is still unclear. Methods: In study 1, in 157 consecutive patients with HCV-related compensated cirrhosis, treatment efficacy with interferon plus ribavirin therapy was evaluated for 48 weeks of HCV genotype 1b (HCV-1b) or 24 weeks of HCV-2a/2b. In study 2, in 185 consecutive patients with HCV-related compensated cirrhosis, who showed no sustained virological response following the first course of interferon monotherapy, hepatocarcinogenesis rates were evaluated according to the additional treatment, and they were classified into three groups: no treatment, interferon monotherapy, and ribavirin combination therapy. Results: In study 1, in HCV-1b, rates of sustained virological response and sustained biochemical response were 21 and 56%, respectively. In HCV-2a/2b, rates of sustained virological response and sustained biochemical response were 70 and 78%, respectively. In HCV-1b, sustained biochemical response rates were significantly higher than those of sustained virological response. In study 2, the hepatocarcinogenesis rates in ribavirin combination therapy were significantly lower than those in interferon monotherapy and no treatment, respectively. Conclusion: Ribavirin combination therapy for HCV-related compensated cirrhosis reduces the risk of hepatocarcinogenesis in comparison with interferon monotherapy, and higher rates of sustained biochemical response might be associated with lower hepatocarcinogenesis rates.

show abstract

Cancer preventive effect of pegylated interferon α‐2b plus ribavirin in a real‐life clinical setting in Japan: PERFECT interim analysis

Abstract: Several known risk factors for HCC contributed to HCC in patients who received PEG-IFN α-2b and RBV combination therapy, and ALT abnormality after the end of treatment contributes to the onset of HCC in both non-SVR and SVR patients.

Cited by 19 publications

References 22 publications

Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

Efficacy and Safety of Telaprevir-Based Antiviral Treatment for Elderly Patients with Hepatitis C Virus

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

Contact Info

Product

Resources

About